05/18/22 9:15 AMNasdaq : BCTX, BCTXW low floatBriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost EnrollmentBriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that itRHEA-AIneutral
04/13/22 8:00 AMNasdaq : BCTX, BCTXW low floatBriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer ImmunotherapyU.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell’s lead candidate, Bria-IMT™, for the treatment of metastatic breast cancer. Fast Track improves the speed and frequency of communication with FDA, potentially leading to earlier drug approval and access by patients.RHEA-AIvery positive
04/12/22 4:30 PMNasdaq : BCTX, BCTXW low floatBriaCell Presents Development Details of Bria-OTS™ Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022Based on clinical data with Bria-IMT™, BriaCell has developed Bria-OTS™, an off-the-shelf (i.e. pre-manufactured) personalized immunotherapy. Bria-OTS™ will be used to treat patients with advanced breast cancer, providing patients with readily available personalized treatment. PHILADELPHIA andRHEA-AIneutral
04/07/22 8:30 AMNasdaq : BCTX, BCTXW clinical triallow floatBriaCell advances preparatory work for new Bria-OTS™ breast cancer clinical trialBria-OTS™ would build on BriaCell’s existing clinical trial data with Bria-IMT™, treating each patient with the optimized pre-manufactured Bria-OTS™ formulation based on HLA-type. BriaCell and National Cancer Institute collaborating on Bria-OTS™, BriaCell’s off-the-shelf personalized immunotherapy,RHEA-AIneutral
02/28/22 8:00 AMNasdaq : BCTX, BCTXW clinical triallow floatBriaCell Adds Two Clinical Trial Sites to Accelerate Patient EnrollmentBriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that itRHEA-AIneutral
02/23/22 8:00 AMNasdaq : BCTX, BCTXW managementlow floatBriaCell Appoints Leading Immunologist Dr. Alexander Kharazi to its Scientific Advisory BoardBriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased toRHEA-AIvery positive
02/16/22 8:00 AMNasdaq : BCTX, BCTXW managementlow floatBriaCell Appoints Renowned Oncologist, Giuseppe Del Priore, MD, MPH, as Chief Medical Officer BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces theRHEA-AIneutral
02/10/22 8:00 AMNasdaq : BCTX, BCTXW buybackconferenceslow floatBriaCell to Present at the AACR 2022; Provides Corporate Buyback and Insider Buying UpdateBriaCell selected to present at the American Association for Cancer Research (AACR) Annual Meeting 2022 Corporate buyback program continues; 1,031,672 shares and 200,740 warrants repurchased since program commencement Insiders intend to acquire up to approximately 10% of BriaCell’s common shares,RHEA-AIneutral
01/19/22 4:57 PMNasdaq : BCTX, BCTXW low floatBriaCell Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of ShareholdersBriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), is pleased to announce that all resolutions proposed to shareholders at the Annual and Special Meeting of Shareholders (theRHEA-AIneutral
12/29/21 8:48 PMNasdaq : BCTX, BCTXW low floatBriaCell to Uplist and Trade on the Toronto Stock Exchange from TSX Venture Exchange under 'BCT'; Remains 'BCTX' on NasdaqBriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and otherRHEA-AIneutral
